Literature DB >> 8229470

Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.

D A Bellnier1, B W Henderson, R K Pandey, W R Potter, T J Dougherty.   

Abstract

The combination of the new photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) and laser light of wavelength 665 nm showed antitumor activity against two s.c.-implanted murine tumors. HPPH also sensitized normal mouse foot tissue to light but photosensitivity decreased rapidly with time after HPPH administration. Mechanistic studies revealed that HPPH induced little direct tumor cell toxicity but was an effective mediator of vascular photodamage. Pharmacokinetic studies following intravenous injection of 1 mg [14C]HPPH per kilogram revealed a biexponential decay with time, with plasma alpha and beta half-lives of 0.69 and 21 h respectively. Fecal excretion was the primary route of elimination. The highest levels of [14C]HPPH were found in the liver, which also showed the greatest long-term retention. The sequence of decreasing uptake levels was the liver, adrenals, lung, spleen, kidney, urinary bladder, heart, eye, skin, pancreas, muscle, testes, fat and brain. This distribution correlated with the relative blood perfusion rates in the tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229470     DOI: 10.1016/1011-1344(93)80131-r

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  22 in total

1.  Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Authors:  Theresa M Busch; Hsing-Wen Wang; E Paul Wileyto; Guoqiang Yu; Ralph M Bunte
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

2.  Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris.

Authors:  T A Ciulla; M H Criswell; W J Snyder; W Small
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

3.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

4.  Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model.

Authors:  Craig E Grossman; Stephen Pickup; Amy Durham; E Paul Wileyto; Mary E Putt; Theresa M Busch
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

5.  Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Authors:  Hector R Nava; Shyam S Allamaneni; Thomas J Dougherty; Michele T Cooper; Wei Tan; Gregory Wilding; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

6.  IL-6 potentiates tumor resistance to photodynamic therapy (PDT).

Authors:  Craig M Brackett; Barbara Owczarczak; Kimberley Ramsey; Patricia G Maier; Sandra O Gollnick
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

7.  Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.

Authors:  Janet Morgan; Jennifer D Jackson; Xiang Zheng; Suresh K Pandey; Ravindra K Pandey
Journal:  Mol Pharm       Date:  2010-09-01       Impact factor: 4.939

8.  Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles.

Authors:  Anurag Gupta; Shouyan Wang; Paula Pera; K V R Rao; Nayan Patel; Tymish Y Ohulchanskyy; Joseph Missert; Janet Morgan; Yong-Eun Koo-Lee; Raoul Kopelman; Ravindra K Pandey
Journal:  Nanomedicine       Date:  2011-11-22       Impact factor: 5.307

9.  Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method.

Authors:  Kowthavarapu Venkata Krishna; Ranendra Narayana Saha; Anu Puri; Mathias Viard; Bruce A Shapiro; Sunil Kumar Dubey
Journal:  Photochem Photobiol Sci       Date:  2019-05-15       Impact factor: 3.982

10.  Photodynamic Therapy for Cancer and for Infections: What Is the Difference?

Authors:  Sulbha K Sharma; Pawel Mroz; Tianhong Dai; Ying-Ying Huang; Tyler G St Denis; Michael R Hamblin
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.